• The major actions of treprostinil appear to be similar to the effects of epoprostenol (Flolan® or Veletri®) and include vasodilatation of the pulmonary and systemic vascular beds (widening of narrowed blood vessels in the lung and other parts of the body) and inhibition of platelet aggregation (clumping). (patientworthy.com)
  • Sterile Diluent for Flolan or Sterile Diluent for Epoprostenol), Sterile Water for Injection, or 0.9% Sodium Chloride Injection prior to administration. (rxlist.com)
  • Intravenous therapy with VELETRI ® will likely be needed for prolonged periods, possibly years, so consider the patient's capacity to accept and care for a permanent intravenous catheter and infusion pump. (janssencarepath.com)
  • Prescribing information states that Veletri is taken as a continuous intravenous infusion through a thin, flexible tube called a Hickman or Groshong line. (myphteam.com)
  • Reconstitute VELETRI ® only as directed using Sterile Water for Injection, USP, or Sodium Chloride 0.9% Injection, USP. (janssencarepath.com)
  • VELETRI ® is a potent pulmonary and systemic vasodilator. (janssencarepath.com)
  • Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. (lgmpharma.com)
  • Epoprostenol is a strong vasodilator of all vascular beds. (medscape.com)
  • Veletri can also cause dizziness. (rxwiki.com)
  • Because epoprostenol is metabolized rapidly, even brief interruptions in the delivery of VELETRI ® may result in symptoms associated with rebound pulmonary hypertension including dyspnea, dizziness, and asthenia. (janssencarepath.com)
  • Abrupt withdrawal (including interruptions in drug delivery) or sudden large reductions in dosage of VELETRI ® may result in symptoms associated with rebound pulmonary hypertension, including dyspnea, dizziness, and asthenia. (janssencarepath.com)
  • Dosage of VELETRI ® during chronic use should be adjusted at the first sign of recurrence or worsening of symptoms attributable to pulmonary hypertension or the occurrence of adverse events associated with epoprostenol. (janssencarepath.com)
  • During chronic use, deliver VELETRI ® continuously on an ambulatory basis through a permanent indwelling central venous catheter. (janssencarepath.com)
  • VELETRI ® is also contraindicated in patients with known hypersensitivity to the drug or to structurally related compounds. (janssencarepath.com)
  • Veletri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). (myphteam.com)
  • Veletri is a prescription medication used to treat pulmonary arterial hypertension in order to improve exercise capacity. (rxwiki.com)
  • VELETRI ® should be used only by clinicians experienced in the diagnosis and treatment of pulmonary hypertension. (janssencarepath.com)
  • VELETRI ® is contraindicated in patients with congestive heart failure due to severe left ventricular systolic dysfunction. (janssencarepath.com)
  • Rare but serious side effects listed for Veletri include hypotension (low blood pressure), pulmonary edema (swelling and fluid in the lungs), and bleeding. (myphteam.com)
  • This is not a complete list of Veletri side effects. (rxwiki.com)
  • Veletri can cause serious withdrawal side effects. (rxwiki.com)
  • To avoid withdrawal side effects, do not suddenly stop taking Veletri. (rxwiki.com)
  • Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. (lgmpharma.com)
  • VELETRI ® should not be used chronically in patients who during dose initiation develop pulmonary edema, which may be associated with pulmonary veno-occlusive disease. (janssencarepath.com)
  • Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI ® to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (janssencarepath.com)
  • In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. (rxlist.com)
  • Veletri comes in the form of single-use vials that must be reconstituted before administration. (myphteam.com)
  • Do not mix VELETRI ® with any other parenteral medications or solutions prior to or during administration. (janssencarepath.com)
  • To reduce the risk of infection, use aseptic technique in the reconstitution and administration of VELETRI ® and in routine catheter care. (janssencarepath.com)
  • Initiate VELETRI ® in a setting with adequate personnel and equipment for physiologic monitoring and emergency care. (janssencarepath.com)
  • Do not expose VELETRI ® to direct sunlight. (janssencarepath.com)
  • At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. (lgmpharma.com)
  • Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans. (lgmpharma.com)
  • [ 53 ] Nonetheless, the development of acute fulminant pulmonary edema and death have been reported with the infusion of intravenous epoprostenol, even at a very low dose. (medscape.com)
  • Continuous intravenous epoprostenol improves exercise capacity, hemodynamics, and survival in pulmonary hypertension and is the preferred treatment option for the most critically ill patients. (conduent.com)
  • Treprostinil recently received FDA approval for IV use as a bioequivalent of subcutaneous treprostinil, using the same delivery pump used for epoprostenol. (medscape.com)
  • VELETRI is administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump. (nih.gov)
  • Prescribing information states that Veletri is taken as a continuous intravenous infusion through a thin, flexible tube called a Hickman or Groshong line. (myphteam.com)
  • Epoprostenol is usually given as a continuous intravenous infusion (injected slowly). (medlineplus.gov)
  • Because of its short half-life and relative instability, epoprostenol requires continuous intravenous infusion and special handling. (nih.gov)
  • Epoprostenol must be given parenterally and has a short half-life (~6 minutes), for which reasons it is administered as a continuous intravenous infusion. (nih.gov)
  • Epoprostenol comes as a powder in a vial to be mixed with a liquid to be given as an intravenous (into a vein) infusion. (medlineplus.gov)
  • Epoprostenol is provided as a sterile powder in single use vials of 0.5 or 1.5 mg. (nih.gov)
  • Veletri comes in the form of single-use vials that must be reconstituted before administration. (myphteam.com)
  • Rare but serious side effects listed for Veletri include hypotension (low blood pressure), pulmonary edema (swelling and fluid in the lungs), and bleeding. (myphteam.com)
  • also used to treat PAH when another medication ( epoprostenol ) did not help or could not be tolerated. (nih.gov)
  • Epoprostenol is in a class of medications called vasodilators and platelet-aggregation inhibitors. (medlineplus.gov)
  • Epoprostenol is FDA-approved for treatment of IPAH. (medscape.com)
  • Infusion of VELETRI should be initiated at 2 ng/kg/min and increased in increments of 2 ng/kg/min every 15 minutes or longer until dose-limiting pharmacologic effects are elicited or until a tolerance limit to the drug is established. (nih.gov)
  • 10 mL single-dose vial with 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) VELETRI. (nih.gov)
  • Your doctor will probably start you on a low dose of epoprostenol and gradually increase your dose. (medlineplus.gov)
  • Veletri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). (myphteam.com)
  • These highlights do not include all the information needed to use VELETRI safely and effectively. (nih.gov)
  • VELETRI solution reconstituted and immediately diluted to the final concentration in the drug delivery reservoir can be administered per the conditions of use as outlined in Table 1. (nih.gov)
  • Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery. (nih.gov)